14. Transfusion in Hemoglobinopathies


  1. How I treat thalassemiaEliezer A, Patricia J.Blood. 2011;118:3479-88.
  2. When to consider transfusion therapy for patients with non‐transfusion‐dependent thalassaemia.Taher A, Radwan A, Viprakasit V.Vox sanguinis. 2015;108(1):1-10.
  3. Standards for the Clinical Care of Children and Adults with Thalassaemia in the UKAnne Yardumian PT, Farrukh Shah, Kate Ryan,Matthew W Darlison, Elaine Miller, George Constantinou3rd ed. London, UK: Thalassaemia Society; 2016.
  4. Guidelines for the clinical care of patients with thalassemia in Canada. Anemia Institute for Research and Education & Thalassemia Foundation of Canada. Sayani F, Warner M, Wu J, Wong-Rieger D, Humphreys K, Odame I. Canadian Pediatric Society, 2009
  5. Blood group genotyping: from patient to high-throughput donor screeningVeldhuisen B, van der Schoot CE, de Haas MVox sanguinis. 2009;97(3):198-206.
  6. Challenges of alloimmunization in patients with haemoglobinopathiesChou ST, Liem RI, Thompson AABritish journal of haematology. 2012;159(4):394-404.
  7. Immune regulation in chronically transfused allo-antibody responder and nonresponder patients with sickle cell disease and beta-thalassemia major.Bao W, Zhong H, Li X, Lee MT, Schwartz J, Sheth S, et al. American journal of hematology. 2011;86(12):1001-6.
  8. Standards of care guidelines for thalassemia.Vichinsky E, Levine L, Bhatia S, Bojanowski J, Coates T, Foote D, et al.Children’s Hospital & Research Center Oakland, USA. 2008.
  9. Guidelines for the management of transfusion dependent thalassaemia (TDT).Cappellini M-D, Cohen A, Porter J, Taher A, Viprakasit V.TIF publication. 2014(20).
  10. Guidelines for the management of non transfusion dependent thalassaemia (NTDT): Thalassaemia Taher A, Vichinsky E, Musallam K, Cappellini M-D, Viprakasit V.International Federation, Nicosia, Cyprus; 2013.
  11. Guidelines for diagnosis and management of Beta-thalassemia intermedia.Karimi M, Cohan N, De Sanctis V, Mallat NS, Taher A.Pediatric hematology and oncology. 2014;31(7):583-96.
  12. Sickle cell disease in childhood: standards and guidelines for clinical care: NHS Sickle Cell and Thalassaemia Screening ProgrammeDick M. NHS 2010
  13. Standards for the clinical care of adults with sickle cell disease in the UKOlujohungbe A, Bennett L, Chapman C, Davis B, Howard J, Ryan K, et al.Sickle Cell Society, London, UK. 2008.
  14. Guidelines on red cell transfusion in sickle cell disease Part II: indications for transfusion. Davis BA, Allard S, Qureshi A, Porter JB, Pancham S, Win N, et al. British journal of haematology. 2016.
  15. Acute multiorgan failure syndrome: a potentially catastrophic complication of severe sickle cell pain episodes. Hassell KL, Eckman JR, Lane PA. The American journal of medicine. 1994;96(2):155-62.
  16. Guideline on the management of acute chest syndrome in sickle cell disease. Howard J, Hart N, Roberts‐Harewood M, Cummins M, Awogbade M, Davis B. British journal of haematology. 2015;169(4):492-505.
  17. The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial. Howard J, Malfroy M, Llewelyn C, Choo L, Hodge R, Johnson T, et al. The Lancet. 2013;381(9870):930-8.
  18. Indications for red cell transfusion in sickle cell disease. Ohene-Frempong K, Seminars in hematology; 2001: Elsevier.
  19. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al. The New England journal of medicine. 1998;339(1):5-11.
  20. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease.Adams RJ, Brambilla D. The New England journal of medicine. 2005;353(26):2769-78.
  21. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia.DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, et al. New England Journal of Medicine. 2014;371(8):699-710.
  22. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, et al. The Lancet. 2016;387(10019):661-70.
  23. Stroke with transfusions changing to hydroxyurea (SWiTCH). Ware RE, Helms RW. Blood. 2012:blood-2011-11-392340.
  24. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. Vichinsky EP, Haberkern CM, Neumayr L, Earles AN, Black D, Koshy M, et al. New England Journal of Medicine. 1995;333(4):206-14.
  25. Pregnancy and sickle cell disease: A review of the current literature. Boga C, Ozdogu H. Critical reviews in oncology/hematology. 2016;98:364-74.
  26. A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. Cazzola M, Borgna-Pignatti C, Locatelli F, Ponchio L, Beguin Y, De Stefano P. Transfusion. 1997;37(2):135-40.
  27. Guidelines on transfusion for fetuses, neonates and older children. New HV, Berryman J, Bolton‐Maggs PH, Cantwell C, Chalmers EA, Davies T, et al. British journal of haematology. 2016;175(5):784-828.
  28. Calculating the required transfusion volume in children. Davies P, Robertson S, Hegde S, Greenwood R, Massey E, Davis P. Transfusion. 2007;47(2):212-6.
  29. Transfusion requirements and effects in patients with thalassaemia major. Rebulla P, Modell B. The Lancet. 1991;337(8736):277-80.
  30. Optimal management of β thalassaemia intermedia. Taher AT, Musallam KM, Cappellini MD, Weatherall DJ.British journal of haematology. 2011;152(5):512-23.
  31. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, et al. Blood. 2010;115(10):1886-92.
  32. Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia. Haidar R, Mhaidli H, Taher AT.European Spine Journal. 2010;19(6):871-8.